Riociguat for the Treatment of Pulmonary Arterial Hypertension
Top Cited Papers
- 25 July 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (4), 330-340
- https://doi.org/10.1056/nejmoa1209655
Abstract
Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension.This publication has 25 references indexed in Scilit:
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL RegistrySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension TrialsCirculation, 2012
- Mechanisms of disease: pulmonary arterial hypertensionNature Reviews Cardiology, 2011
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II studyEuropean Respiratory Journal, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- ACCF/AHA 2009 Expert Consensus Document on Pulmonary HypertensionCirculation, 2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2000